Announced
Completed
Financials
Tags
pharmaceuticals company
Domestic
Majority
Public
Friendly
Single Bidder
Pharmaceuticals
United States
Acquisition
Completed
Synopsis
Amgen, a biotechnology company, completed the acquisition of ChemoCentryx, a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, for $3.7bn. "The acquisition of ChemoCentryx represents a compelling opportunity for Amgen to add to our decades-long leadership in inflammation and nephrology with TAVNEOS, a transformative, first-in-class treatment for ANCA-associated vasculitis. We are excited to join in the TAVNEOS launch and help many more patients with this serious and sometimes life-threatening disease for which there remains significant unmet medical need. We also look forward to welcoming the highly skilled team from ChemoCentryx that shares our passion for serving patients suffering from serious diseases," Robert A. Bradway, Amgen Chairman and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.